Advertisement

Topics

Bayer’s stivarga receives EU marketing approval for HCC treatment

19:00 EDT 7 Aug 2017 | Pharmaceutical Technology

The European Commission (EC) has granted marketing authorisation for Bayer’s stivarga (regorafenib) used for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with nexavar (sorafenib).

Original Article: Bayer’s stivarga receives EU marketing approval for HCC treatment

NEXT ARTICLE

More From BioPortfolio on "Bayer’s stivarga receives EU marketing approval for HCC treatment"

Quick Search
Advertisement
 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...